Compare Alcon AG (ALC) vs Diageo plc (DEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Diageo plc — how do they compare? Alcon AG trades at $66.93 (market cap $32.69B), while Diageo plc trades at $81.06 (market cap $45.92B). The key difference: Diageo plc is the larger of the two by market cap, and Diageo plc pays the higher dividend (4.01%). Which is the better fit depends on your goals.
| ALC | DEO | |
|---|---|---|
Market Cap | $32.69B | $45.92B |
Sector | Health | Technology |
52-Week High | $92.22 | $115.33 |
52-Week Low | $62.02 | $72.47 |
Enterprise Value | $36.28B | $66.74B |
Dividend Yield | 0.54% | 4.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Diageo (DEO) trades at $81.67, down 0.6% on the day, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a 12.19% net margin and 22.29% ROE, but faces headwinds in the US spirits market. Recent news highlights CEO Dave Lewis's upcoming strategy update amid concerns over US demand and promotional pressures.
The outlook is cautious with analyst consensus leaning buy (48.65%) but significant hold ratings (43.24%). Key risks include US market weakness and shifting consumer trends, while opportunities lie in premiumization and innovation. The stock's valuation at a P/E of 18.87 appears reasonable if recovery initiatives gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
